Your Cart
Your cart is empty

Looks like you haven't added any test / checkup to your cart

Add Test / Checkup
User Sign In Health checkup offers

Book IHC Test for Estrogen Receptor

Estrogen Receptor (ER) is a type of protein found within cells that is activated by the hormone estrogen. The presence and amount of this receptor in cells, particularly cancer cells, can provide important information about the nature of the disease and its potential response to certain treatments. The Immunohistochemistry (IHC) test for Estrogen Receptor (ER) helps detect the presence and quantity of this receptor in a sample of tissue.

Breast cancer cells, for example, often have these receptors, and their presence indicates that the cells may respond to hormonal therapies. These types of therapies can block the ability of estrogen to promote the growth of breast cancer cells. The ER status of cancer can significantly impact the treatment strategies and has important prognostic implications.

  • Test Name: IHC – ER
  • Sample Type: Tissue
  • Preparations Required: No specific patient preparation like fasting or water restrictions is needed for this test. Instructions for the biopsy procedure will be provided by the healthcare provider.
  • Report Time: 3 days

Home Sample Collection Process

Book your convenient slot
Book your convenient slot
Sample Collection by Phlebotomist
Sample Collection by Phlebotomist
Reporting of the sample at lab
Reporting of the sample at lab
Download Reports
Download Reports
Frequently Asked Questions

The IHC - ER test is critical in determining the presence and amount of estrogen receptors in cells, especially in cases of breast cancer. This information can guide treatment strategies and provide prognosis insights.

No, fasting is not necessary for this test.

Your healthcare provider will order this test if you have been diagnosed with cancer, especially breast cancer, to determine the best treatment strategy.

The IHC - ER test measures the presence and quantity of estrogen receptors in a tissue sample. High levels of estrogen receptors can indicate that the cancer may respond to hormonal therapy.

This test is usually performed when cancer is initially diagnosed and may be repeated if there's a recurrence to reassess the status of the disease.

In normal, noncancerous cells, estrogen receptors may be present but in a lesser amount compared to cancerous cells. However, the interpretation of test results should always be done in the context of other clinical and diagnostic findings.

This test involves a biopsy procedure. It's essential to provide your complete health history, including any medications or supplements you're taking, to your healthcare provider. Some medications and supplements can affect the results of the test.

The levels of ER in a tissue sample can be affected by the stage and type of the disease, the individual's genetic makeup, and the body's hormonal environment.

Nonmodifiable factors include genetic predisposition and age. Postmenopausal women, for instance, might have different ER levels in their cells compared to premenopausal women.

Modifiable factors include lifestyle habits such as diet, exercise, and alcohol consumption, which can influence hormone levels and, consequently, ER levels in cells.

Abnormal results should be discussed with the healthcare provider managing your case. This could be an oncologist or a hematologist.

The biopsy procedure involves extracting a small piece of tissue from the body for examination. The specifics of the procedure depend on the location of the biopsy.

As with any procedure, there are some risks associated with a biopsy, such as infection, bleeding, and reactions to anesthesia. However, these risks are generally low, and your healthcare provider will take measures to minimize them.

If you are pregnant and need this test, discuss the potential risks and benefits with your healthcare provider. The decision will be based on your specific situation, considering factors like the urgency of the diagnosis and the location of the biopsy.

Yes, the results of this test can guide the choice of treatments. If the cancer cells have estrogen receptors, hormone therapy might be an effective treatment strategy.

No, the IHC - ER test does not diagnose cancer on its own. It is used in conjunction with other diagnostic procedures like biopsy and imaging tests to confirm a cancer diagnosis and guide treatment options.

While the IHC - ER test is most commonly used for breast cancer, it may also provide useful information for other types of cancers, such as ovarian or uterine cancer. The use of this test will depend on the clinical judgment of your healthcare provider.

Yes, other similar tests include the progesterone receptor (PR) test and HER2/neu test. Like the IHC - ER test, these tests are used to determine the presence of specific receptors in cancer cells that can influence treatment strategies.

The test itself is not painful, but the biopsy procedure to obtain the tissue sample may cause discomfort or slight pain. Your healthcare provider will usually administer local anesthesia to minimize any discomfort during the procedure.

If the cancer cells do not have estrogen receptors, it means that the cancer is less likely to respond to hormone therapy. In such cases, other treatment strategies such as chemotherapy, radiation therapy, or targeted therapies may be considered.

In the grand scheme of your health journey, the IHC - ER test provides critical information that helps personalize your treatment plan. Regardless of the results, it is essential to remember that multiple treatment options are available and advancements in medicine continue to provide hope. It's crucial to have open discussions with your healthcare provider to understand your results and the next steps in your treatment plan.

Schedule Test in Your Available Time
Locations Near You in Hyderabad
  • 4KM from Madhapur
  • 3KM from Banjara Hills
  • 1.9KM from Yusufguda
  • 3KM from Madhura Nagar
  • 5KM from Shaikpet